These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28782211)

  • 1. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.
    Lee OL; Horvath N; Lee C; Joshua D; Ho J; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Talaulikar D; Brown R; Augustson B; Ling S; Jaksic W; Gibson J; Kalff A; Johnston A; Kalro A; Ward C; Prince HM; Zannettino A
    Intern Med J; 2017 Aug; 47(8):938-951. PubMed ID: 28782211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E; Dimopoulos MA; Berenson J
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trials of bisphosphonates in multiple myeloma.
    Mahindra A; Pozzi S; Raje N
    Clin Adv Hematol Oncol; 2012 Sep; 10(9):582-7. PubMed ID: 23073123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Jaw osteonecrosis associated with use of bisphosphonates and chemotherapy: paradoxical complication of treatment of bone lesions in multiple myeloma patients.
    Capalbo S; Delia M; Diomede D; Dargenio M; Chiefa A; Favia G; Liso V
    Int J Hematol; 2006 Jun; 83(5):439-42. PubMed ID: 16787865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate complications including osteonecrosis of the jaw.
    Mehrotra B; Ruggiero S
    Hematology Am Soc Hematol Educ Program; 2006; ():356-60, 515. PubMed ID: 17124083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Jaw avascular osteonecrosis after treatment of multiple myeloma with zoledronate.
    Lobato JV; Maurício AC; Rodrigues JM; Cavaleiro MV; Cortez PP; Xavier L; Botelho C; Hussain NS; Santos JD
    J Plast Reconstr Aesthet Surg; 2008; 61(1):99-106. PubMed ID: 18068658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw.
    Musolino C; Oteri G; Allegra A; Mania M; D'Ascola A; Avenoso A; Innao V; Allegra AG; Campo S
    Ann Hematol; 2018 Jul; 97(7):1259-1269. PubMed ID: 29546453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment.
    Migliorati CA; Siegel MA; Elting LS
    Lancet Oncol; 2006 Jun; 7(6):508-14. PubMed ID: 16750501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonate therapy for skeletal malignancies and metastases: impact on jaw bones and prosthodontic concerns.
    Tripathi A; Pandey S; Singh SV; Kumar Sharma N; Singh R
    J Prosthodont; 2011 Oct; 20(7):601-3. PubMed ID: 21883630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Why osteonecrosis of the jaw after bisphosphonates treatment is more frequent in multiple myeloma than in solid tumors.
    Delibasi T; Altundag K; Kanlioglu Y
    J Oral Maxillofac Surg; 2006 Jun; 64(6):995-6. PubMed ID: 16713825
    [No Abstract]   [Full Text] [Related]  

  • 11. International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
    Terpos E; Morgan G; Dimopoulos MA; Drake MT; Lentzsch S; Raje N; Sezer O; García-Sanz R; Shimizu K; Turesson I; Reiman T; Jurczyszyn A; Merlini G; Spencer A; Leleu X; Cavo M; Munshi N; Rajkumar SV; Durie BG; Roodman GD
    J Clin Oncol; 2013 Jun; 31(18):2347-57. PubMed ID: 23690408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
    Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
    Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management.
    Ruggiero SL; Fantasia J; Carlson E
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Oct; 102(4):433-41. PubMed ID: 16997108
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous bisphosphonate therapy and bisphosphonate-related osteonecrosis of the jaws.
    Dodson TB
    J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):44-52. PubMed ID: 19371814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis.
    Ding X; Fan Y; Ma F; Li Q; Wang J; Zhang P; Yuan P; Xu B
    Breast; 2012 Aug; 21(4):544-9. PubMed ID: 22627092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate-associated osteonecrosis: a clinician's reference to patient management.
    Grewal VS; Fayans EP
    Todays FDA; 2008 Aug; 20(8):38-41, 43-6. PubMed ID: 18767452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone necrosis of the jaws associated with bisphosphonate treatment: a report of twenty-nine cases.
    Merigo E; Manfredi M; Meleti M; Guidotti R; Ripasarti A; Zanzucchi E; D'Aleo P; Corradi D; Corcione L; Sesenna E; Ferrari S; Poli T; Bonaninil M; Vescovi P
    Acta Biomed; 2006 Aug; 77(2):109-17. PubMed ID: 17172192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.
    Chang ST; Tenforde AS; Grimsrud CD; O'Ryan FS; Gonzalez JR; Baer DM; Chandra M; Lo JC
    Bone; 2012 Sep; 51(3):524-7. PubMed ID: 22634175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
    Raje N; Vescio R; Montgomery CW; Badros A; Munshi N; Orlowski R; Hadala JT; Warsi G; Argonza-Aviles E; Ericson SG; Anderson KC
    Clin Cancer Res; 2016 Mar; 22(6):1378-84. PubMed ID: 26644410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.